Protein-binding microarray analysis of tumor suppressor AP2α target gene specificity

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Kerschgens, Jan ^a   Renaud, Stéphanie ^a   Schütz, Frédéric ^a   Grasso, Luigino ^b   Egener Kuhn, Tanja ^a,b   Delaloye, Jean François ^c   Lehr, Hans Anton ^c   Vogel, Horst ^b   Mermod, Nicolas ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b EPFL   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; TRANSCRIPTION FACTOR AP 2; TUMOR SUPPRESSOR PROTEIN;

ACCURACY; ACTIVATING PROTEIN 2 ALPHA GENE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BREAST TUMOR; CANCER RESISTANCE; CARCINOMA CELL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INTERACTION; GENE REGULATORY NETWORK; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; PROTEIN BINDING; QUANTITATIVE ANALYSIS; REGULATORY SEQUENCE; SENSITIVITY AND SPECIFICITY; SURFACE PLASMON RESONANCE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; BINDING SITE; DNA MICROARRAY; FEMALE; GENETICS; HEALTH; HUMAN GENOME; METABOLISM; NEOPLASM; NUCLEOTIDE SEQUENCE; REPRODUCIBILITY; TUMOR CELL LINE;

BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; FEMALE; GENE REGULATORY NETWORKS; GENOME, HUMAN; HEALTH; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION FACTOR AP-2; TUMOR SUPPRESSOR PROTEINS;

EID: 80051849185     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022895     Document Type: Article

References (73)

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921.
2. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, et al. (2001) The sequence of the human genome. Science 291: 1304-1351.
3. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. (2002) The human genome browser at UCSC. Genome Res 12: 996-1006.
4. Karolchik D, Kuhn RM, Baertsch R, Barber GP, Clawson H, et al. (2008) The UCSC Genome Browser Database: 2008 update. Nucleic Acids Res 36: D773-779.
5. Thomas DJ, Rosenbloom KR, Clawson H, Hinrichs AS, Trumbower H, et al. (2007) The ENCODE Project at UC Santa Cruz. Nucleic Acids Res 35: D663-667.
6. Kent WJ, (2002) BLAT-the BLAST-like alignment tool. Genome Res 12: 656-664.
7. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, et al. (2004) The UCSC Table Browser data retrieval tool. Nucleic Acids Res 32: D493-496.
8. Croce CM, (2008) Oncogenes and cancer. N Engl J Med 358: 502-511.
9. Yokota J, (2000) Tumor progression and metastasis. Carcinogenesis 21: 497-503.
10. Bulyk ML, (2006) DNA microarray technologies for measuring protein-DNA interactions. Curr Opin Biotechnol 17: 422-430.
11. Berger MF, Philippakis AA, Qureshi AM, He FS, Estep PW 3rd, et al. (2006) Compact, universal DNA microarrays to comprehensively determine transcription-factor binding site specificities. Nat Biotechnol 24: 1429-1435.
12. Berger MF, Bulyk ML, (2006) Protein binding microarrays (PBMs) for rapid, high-throughput characterization of the sequence specificities of DNA binding proteins. Methods Mol Biol 338: 245-260.
13. Mukherjee S, Berger MF, Jona G, Wang XS, Muzzey D, et al. (2004) Rapid analysis of the DNA-binding specificities of transcription factors with DNA microarrays. Nat Genet 36: 1331-1339.
14. Bulyk ML, Huang X, Choo Y, Church GM, (2001) Exploring the DNA-binding specificities of zinc fingers with DNA microarrays. Proc Natl Acad Sci U S A 98: 7158-7163.
15. Bulyk ML, Gentalen E, Lockhart DJ, Church GM, (1999) Quantifying DNA-protein interactions by double-stranded DNA arrays. Nat Biotechnol 17: 573-577.
16. Bolotin E, Liao H, Ta TC, Yang C, Hwang-Verslues W, et al. (2010) Integrated approach for the identification of human hepatocyte nuclear factor 4alpha target genes using protein binding microarrays. Hepatology 51: 642-653.
17. Imagawa M, Chiu R, Karin M, (1987) Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP. Cell 51: 251-260.
18. Mitchell PJ, Wang C, Tjian R, (1987) Positive and negative regulation of transcription in vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen. Cell 50: 847-861.
19. Nyborg JK, Dynan WS, (1990) Interaction of cellular proteins with the human T-cell leukemia virus type I transcriptional control region. Purification of cellular proteins that bind the 21-base pair repeat elements. J Biol Chem 265: 8230-8236.
20. Eckert D, Buhl S, Weber S, Jager R, Schorle H, (2005) The AP-2 family of transcription factors. Genome Biol 6: 246.
21. Pellikainen JM, Kosma VM, (2007) Activator protein-2 in carcinogenesis with a special reference to breast cancer-a mini review. Int J Cancer 120: 2061-2067.
22. Wajapeyee N, Somasundaram K, (2003) Cell cycle arrest and apoptosis induction by activator protein 2alpha (AP-2alpha) and the role of p53 and p21WAF1/CIP1 in AP-2alpha-mediated growth inhibition. J Biol Chem 278: 52093-52101.
23. Wajapeyee N, Britto R, Ravishankar HM, Somasundaram K, (2006) Apoptosis induction by activator protein 2alpha involves transcriptional repression of Bcl-2. J Biol Chem 281: 16207-16219.
24. Wajapeyee N, Raut CG, Somasundaram K, (2005) Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res 65: 8628-8634.
25. Williams T, Tjian R, (1991) Characterization of a dimerization motif in AP-2 and its function in heterologous DNA-binding proteins. Science 251: 1067-1071.
26. Williams T, Admon A, Luscher B, Tjian R, (1988) Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements. Genes Dev 2: 1557-1569.
27. Williams T, Tjian R, (1991) Analysis of the DNA-binding and activation properties of the human transcription factor AP-2. Genes Dev 5: 670-682.
28. Bauer R, Imhof A, Pscherer A, Kopp H, Moser M, et al. (1994) The genomic structure of the human AP-2 transcription factor. Nucleic Acids Res 22: 1413-1420.
29. Orso F, Penna E, Cimino D, Astanina E, Maione F, et al. (2008) AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs. FASEB J 22: 2702-2714.
30. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, et al. (2003) A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A 100: 8164-8169.
31. Kerschgens J, Egener-Kuhn T, Mermod N, (2009) Protein-binding microarrays: probing disease markers at the interface of proteomics and genomics. Trends Mol Med 15: 352-358.
32. Egener T, Roulet E, Zehnder M, Bucher P, Mermod N, (2005) Proof of concept for microarray-based detection of DNA-binding oncogenes in cell extracts. Nucleic Acids Res 33: e79.
33. Benetti R, Del Sal G, Monte M, Paroni G, Brancolini C, et al. (2001) The death substrate Gas2 binds m-calpain and increases susceptibility to p53-dependent apoptosis. EMBO J 20: 2702-2714.
34. Sgorbissa A, Benetti R, Marzinotto S, Schneider C, Brancolini C, (1999) Caspase-3 and caspase-7 but not caspase-6 cleave Gas2 in vitro: implications for microfilament reorganization during apoptosis. J Cell Sci 112 (Pt 23): 4475-4482.
35. Planque C, de Monte M, Guyetant S, Rollin J, Desmazes C, et al. (2005) KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer. Biochem Biophys Res Commun 329: 1260-1266.
36. Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropoulou G, et al. (2006) Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. J Biol Chem 281: 12743-12750.
37. Shinoda Y, Kozaki K, Imoto I, Obara W, Tsuda H, et al. (2007) Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells. Cancer Sci 98: 1078-1086.
38. Thomadaki H, Mavridis K, Talieri M, Scorilas A, (2009) Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thromb Haemost 101: 373-380.
39. Babini E, Bertini I, Capozzi F, Del Bianco C, Hollender D, et al. (2004) Solution structure of human beta-parvalbumin and structural comparison with its paralog alpha-parvalbumin and with their rat orthologs. Biochemistry 43: 16076-16085.
40. Fohr UG, Weber BR, Muntener M, Staudenmann W, Hughes GJ, et al. (1993) Human alpha and beta parvalbumins. Structure and tissue-specific expression. Eur J Biochem 215: 719-727.
41. Schwartz B, Melnikova VO, Tellez C, Mourad-Zeidan A, Blehm K, et al. (2007) Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene 26: 4049-4058.
42. Johnson W, Albanese C, Handwerger S, Williams T, Pestell RG, et al. (1997) Regulation of the human chorionic gonadotropin alpha- and beta-subunit promoters by AP-2. J Biol Chem 272: 15405-15412.
43. Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, et al. (2007) Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther 6: 1650-1660.
44. Mertens PR, Steinmann K, Alfonso-Jaume MA, En-Nia A, Sun Y, et al. (2002) Combinatorial interactions of p53, activating protein-2, and YB-1 with a single enhancer element regulate gelatinase A expression in neoplastic cells. J Biol Chem 277: 24875-24882.
45. Qin H, Sun Y, Benveniste EN, (1999) The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 274: 29130-29137.
46. Hoh J, Jin S, Parrado T, Edington J, Levine AJ, et al. (2002) The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci U S A 99: 8467-8472.
47. Ohki R, Nemoto J, Murasawa H, Oda E, Inazawa J, et al. (2000) Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem 275: 22627-22630.
48. Taura M, Eguma A, Suico MA, Shuto T, Koga T, et al. (2008) p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines. Mol Cell Biol 28: 6557-6567.
49. Vrba L, Junk DJ, Novak P, Futscher BW, (2008) p53 induces distinct epigenetic states at its direct target promoters. BMC Genomics 9: 486.
50. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, et al. (2006) A global map of p53 transcription-factor binding sites in the human genome. Cell 124: 207-219.
51. Batsche E, Muchardt C, Behrens J, Hurst HC, Cremisi C, (1998) RB and c-Myc activate expression of the E-cadherin gene in epithelial cells through interaction with transcription factor AP-2. Mol Cell Biol 18: 3647-3658.
52. McPherson LA, Loktev AV, Weigel RJ, (2002) Tumor suppressor activity of AP2alpha mediated through a direct interaction with p53. J Biol Chem 277: 45028-45033.
53. Lundwall A, Brattsand M, (2008) Kallikrein-related peptidases. Cell Mol Life Sci 65: 2019-2038.
54. Obiezu CV, Diamandis EP, (2005) Human tissue kallikrein gene family: applications in cancer. Cancer Lett 224: 1-22.
55. Yousef GM, Diamandis EP, (2003) An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers. Clin Biochem 36: 443-452.
56. Marreiros A, Dudgeon K, Dao V, Grimm MO, Czolij R, et al. (2005) KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells. Oncogene 24: 637-649.
57. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, et al. (1988) Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48: 6863-6871.
58. R-Development-Core-Team T (2004) R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria R Foundation for Statistical Computing.
59. Smyth GK, Gentleman RC, et al.eds. (2005) Linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor. ed. New York Springer pp. 397-420.
60. Esnault G, Majocchi S, Martinet D, Besuchet-Schmutz N, Beckmann JS, et al. (2009) Transcription factor CTF1 acts as a chromatin domain boundary that shields human telomeric genes from silencing. Mol Cell Biol 29: 2409-2418.
61. Benetti R, Copetti T, Dell'Orso S, Melloni E, Brancolini C, et al. (2005) The calpain system is involved in the constitutive regulation of beta-catenin signaling functions. J Biol Chem 280: 22070-22080.
62. Collavin L, Buzzai M, Saccone S, Bernard L, Federico C, et al. (1998) cDNA characterization and chromosome mapping of the human GAS2 gene. Genomics 48: 265-269.
63. Brancolini C, Bottega S, Schneider C, (1992) Gas2, a growth arrest-specific protein, is a component of the microfilament network system. J Cell Biol 117: 1251-1261.
64. Ishida-Yamamoto A, Deraison C, Bonnart C, Bitoun E, Robinson R, et al. (2005) LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. J Invest Dermatol 124: 360-366.
65. Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, et al. (2005) Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem 280: 14628-14635.
66. Yousef GM, Scorilas A, Chang A, Rendl L, Diamandis M, et al. (2002) Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate 51: 126-132.
67. Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA, (2003) Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res 9: 1710-1720.
68. Yousef GM, Obiezu CV, Jung K, Stephan C, Scorilas A, et al. (2002) Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. Urology 60: 714-718.
69. Dong Y, Matigian N, Harvey TJ, Samaratunga H, Hooper JD, et al. (2008) Tissue-specific promoter utilisation of the kallikrein-related peptidase genes, KLK5 and KLK7, and cellular localisation of the encoded proteins suggest roles in exocrine pancreatic function. Biol Chem 389: 99-109.
70. Pettus JR, Johnson JJ, Shi Z, Davis JW, Koblinski J, et al. (2009) Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity. Histol Histopathol 24: 197-207.
71. Karlen Y, McNair A, Perseguers S, Mazza C, Mermod N, (2007) Statistical significance of quantitative PCR. BMC Bioinformatics 8: 131.
72. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, et al. (2000) CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev 14: 1156-1166.
73. Rozen S, Skaletsky H, (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386.